Crossmark

Documents that mention this clinical trial

Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2025-005969

Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174

POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.833

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
https://doi.org/10.1136/ard-2022-223595

AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2758

Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004202

Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468

Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
https://doi.org/10.1136/ard-2023-224803

POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.836

POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2416

POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2292

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2020-216980

POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
https://doi.org/10.1136/annrheumdis-2023-eular.1996

POS0805 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PATIENT-REPORTED SYMPTOMS OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2197

Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
https://doi.org/10.1136/rmdopen-2023-004040

POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.831

POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1562

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026

POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.786

Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
https://doi.org/10.1136/ard-2024-225933

AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.760

POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.1702

POS0058 IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS AND POST HOC ANALYSES FROM THE BE MOBILE 1 AND 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.4903

Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2025-006013